
Basic information
Grant scheme:
Horizont2020
DG:
REA
Name of the project:
Algae4IBD – from nature to bedside – algae based bio compound for prevention and treatment of inflammation, pain and IBD
Project ID:
101000501
Partners involved:
COORDINATOR
Organisation – MIGAL GALILEE RESEARCH INSTITUTE LTD – MIGAL – Galilee research Institute
BENEFICIARY Organisations
YEMOJA LTD
NORD UNIVERSITET – NORD UNIVERSITET
CENTRO DE CIENCIAS DO MAR DO ALGARVE – CCMAR
ALGAIA
TEAGASC – AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY
UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II – UNINA
SOLARIS LAB SRL
SZEGEDI BIOLOGIAI KUTATOKOZPONT – BIOLOGICAL RESEARCH CENTRE
VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. – VITO
MIKROBIOLOGICKY USTAV AV CR V.V.I
EUROPEAN SCIENCE COMMUNICATION INSTITUTE (ESCI) GGMBH
ELOOP SRL
HUMANITAS UNIVERSITY – HUNIMED
NECTON – COMPANHIA PORTUGUESA DE CULTURAS MARINHAS SA
ENCO SRL – ENCO SRL
GOPSIS LDA
SLOVENSKA POLNOHOSPODARSKA UNIVERZITA V NITRE – SLOVAK UNIVERSITY OF AGRICULTURE IN NITRA
SEA4US BIOTECNOLOGIA E RECURSOS MARINHOS LDA – SEA4US
SYNOVO GMBH – Synovo
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE – UMG AV CR, v. v. i.
Aim of the project:
To address the unmet need in tackling IBD, we intend to use a multi-disciplinary approach to identify bioactive molecules from a botanical source and verify the beneficial claim for IBD prevention and treatment with an innovative technology based on algae. Algae4IBD will perform a detailed research from lab/pilot to market scale to identify how aquatic natural biological resources can be transformed into biologically active compounds to be used for IBD prevention and treatment while preserving the biodiversity of the renewable source
